CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 101 enrolled
Drug / intervention
Percutaneous coronary intervention PROMUS PREMIERdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02230254
NCT02230254N/ACompleted
CompareCT.gov

PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)

Boston Scientific Corporation·interventional·Posted Sep 3, 2014·Updated May 12, 2022

In Brief

A clinical study evaluating Percutaneous coronary intervention PROMUS PREMIER for Atherosclerosis. Completed, enrolled 101 participants.

Detailed Summary

PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 3, 2014
Enrollment StartApr 9, 2014
Primary CompletionJun 22, 2014
Study CompletionJul 31, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.8 years ago

Interventions

Percutaneous coronary intervention PROMUS PREMIERdevice

PROMUS PREMIER